| Item Type | Name |
|
Concept
|
Cytarabine
|
|
Academic Article
|
Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia.
|
|
Academic Article
|
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients
|
|
Academic Article
|
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.
|
|
Academic Article
|
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
|
|
Academic Article
|
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
|
|
Academic Article
|
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
|
|
Academic Article
|
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
|
|
Academic Article
|
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.
|
|
Academic Article
|
Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
|
|
Academic Article
|
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
|
|
Academic Article
|
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
|
|
Academic Article
|
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
|
|
Academic Article
|
Venetoclax-based therapies for acute myeloid leukemia.
|
|
Academic Article
|
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.
|
|
Academic Article
|
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
|
|
Academic Article
|
How I treat acute myeloid leukemia in the era of new drugs.
|
|
Academic Article
|
Single-agent and combination biologics in acute myeloid leukemia.
|
|
Academic Article
|
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
|
|
Academic Article
|
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
|
|
Academic Article
|
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality.
|
|
Academic Article
|
New directions for emerging therapies in acute myeloid leukemia: the next chapter.
|
|
Academic Article
|
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.
|
|
Academic Article
|
Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax.
|
|
Academic Article
|
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
|
|
Academic Article
|
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
|
|
Academic Article
|
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
|
|
Academic Article
|
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
|
|
Academic Article
|
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
|
|
Academic Article
|
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
|
|
Academic Article
|
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
|
|
Academic Article
|
SOHO State of the Art Updates and Next Questions:Harnessing Apoptosis in AML.
|
|
Academic Article
|
Beyond Survival: The US Food and Drug Administration Confirms Surrogate End Points for Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy.
|
|
Academic Article
|
Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.
|
|
Academic Article
|
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials.
|
|
Academic Article
|
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia.
|
|
Academic Article
|
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
|
|
Academic Article
|
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
|
|
Academic Article
|
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
|
|
Academic Article
|
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
|
|
Academic Article
|
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens.
|
|
Academic Article
|
Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy.
|
|
Academic Article
|
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients.
|
|
Academic Article
|
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1.
|
|
Academic Article
|
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
|
|
Academic Article
|
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
|